title: What do prescribers think of biosimilars?
abstract: Until recently, prescribers had to deal with generics, considered to be simple molecules that are easy to copy. But as discussed in this paper, the biodisponibility of generics remains a source of uncertainty. And now there are biosimilars, limited for the time being in the cancer setting to granulocyte-colony stimulating factors (G-CSFs) and epoetins. Soon there will be biosimilar monoclonal antibodies with anticancer activity. Prescribers will ask, as they did for generics, if such drugs have the same activity as originators, if their safety profile is the same, if quality of the production process is guaranteed. Prescribers will want to know if their patients are indeed receiving the prescribed product, and not another. Finally prescribers will want to check that the lower cost of biosimilars will allow them to adhere to international guidelines. This should benefit patients and the community.
authors.affiliation: Institut multidisciplinaire d'oncologie, Clinique de Genolier, CH-1272 Genolier, Switzerland. MAAPRO@genolier.net
authors.forename: M S
authors.initials: MS
authors.lastname: Aapro
mesh_terms: D001688:Biological Products / Q000493:pharmacokinetics*; D011307:Drug Prescriptions; D016568:Drugs, Generic / Q000592:standards*; D006801:Humans; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D013810:Therapeutic Equivalency; D014018:Tissue Distribution
chemical_list: D001688:Biological Products; D016568:Drugs, Generic